Each point was worked out with the data available that day. Scale 0-10: 5 is the index average and 10 is the cap (+3 standard deviations), not perfection. The vertical axis zooms to fit this company, so two charts are not comparable by eye.
Market and Valuation
Price & Market
Prev Close Price:$258.44
Open:$255.65
Day's Low:$252.38
Day's High:$263.99
Bid / Ask:-
Market Cap:43.27B
Enterprise Value:56.61B
52-Week Range
52-Week Low:$154.50
52-Week High:$284.50
Current position in 52-week range
52w Low-52w High
50-Day Avg:$266.06
200-Day Avg:$209.60
Volume
Volume Today:1,321,625
Avg Volume (3m):1,405,545
Avg Volume (10d):1,555,480
52-Week Change:+22.51%
vs S&P 500, 52 weeks:-
Beta:1.17
Valuation Multiples
P/E (trailing):31.95
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 27, 2026. The P/E is the price divided by that EPS.
P/E (forward):18.49
PEG Ratio:0.95
Price / Book:6.50
Price / Sales (TTM):2.50
EV / Revenue:3.27
EV / EBITDA:18.16
Dividends
Current yield:-
Annual Dividend Rate:-
Dividend Trailing:$0.00
Yield Trailing:0.00%
5-Year Avg Yield:-
Payout Ratio:0.00%
Last Ex-Dividend Date:-
Valuation Context
P/E vs sector (indicative)
Most Recent Quarter:-
Fiscal Year (Next):-
Loading historical OHLCV database...
Date
Open
High
Low
Close
Volume
Financial Statements TTM (Trailing 12 Months)
Income Statement
Total Revenue (TTM):17.31B
Gross Profit:5.72B
EBITDA:3.12B
Net Income (TTM):1.39B
Rev Growth (YoY):+8.00%
Earnings Growth (YoY):+8.80%
Quarterly earnings growth (YoY):+5.70%
Margins
Gross Margin:-
EBITDA Margin:-
Operating Margin:-
Net Margin:-
Per Share
EPS Trailing (TTM):$8.22
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 27, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$14.20
Revenue Per Share:$103.50
Cash Per Share:-
Book Value:$40.41
Last Dividend:-
Ex-Dividend Date:-
Last Split:-
Balance Sheet & Liquidity
Total cash:2.42B
Total Debt:16.31B
Net Debt (Debt - Cash):13.89B
Debt / Equity:240.23%
Current Ratio:0.83
Quick Ratio:0.74
Cash Flows
Operating Cash Flow:2.74B
Free Cash Flow (FCF):2.12B
FCF Yield (FCF / Market Cap):-
Enterprise Value:56.61B
EV / Revenue:3.27
EV / EBITDA:18.16
Profitability
ROE (Return on Equity):21.39%
ROA (Return on Assets):5.08%
P/E (trailing):31.95
P/E (forward):18.49
Price / Book:6.50
PEG Ratio:0.95
52-Week Change:+22.51%
S&P 500 change, 52 weeks:+11.37%
Historical Evolution (Last 4 Years)
Income Statement
Balance Sheet
Cash Flow
EPS and Earnings Per Share
Key EPS Metrics
EPS Trailing (TTM):$8.22
Diluted EPS for the last 12 months: the four quarters ended Sep 30, 2026, from the accounts filed with the SEC on Oct 27, 2026. The P/E is the price divided by that EPS.
EPS Forward (Est.):$14.20
P/E (forward):18.49
PEG Ratio:0.95
Growth and Margins
Earnings Growth YoY:-
Quarterly Earnings Growth YoY:-
Rev Growth YoY:-
Net Margin:-
Gross Margin:-
EBITDA Margin:-
Per Share
Revenue Per Share:$103.50
Cash Per Share:-
Book Value:$40.41
Cash Flows (TTM)
Free Cash Flow:2.12B
Operating Cash Flow:2.74B
EBITDA:3.12B
Total Revenue (TTM):17.31B
Net Income (TTM):1.39B
Fiscal Year (Last):-
EPS Surprise History - Last 4 Quarters
Actual vs. Analyst Estimates · Green = beat expectations · Red = missed
Quarter
Period
Actual EPS
Estimated EPS
Difference
Surprise %
Currency
Ownership Structure
Ownership Distribution
% Insiders:-
% Institutional:-
% Inst. (of Float):-
No. of Institutions:-
Visual distribution
InsidersInstitutionalFree Float
Shares & Short Interest
Shares Outstanding:164,800,000
Float (free shares):156,451,232
Short interest (shares):2,992,152
Short % of float:-
Short Ratio (days to cover):1.92
Short interest, prior month:-
Short Interest Date:-
Governance Score (1=Best, 10=Worst)
Overall risk:-
Audit Risk:-
Board risk:-
Compensation Risk:-
Shareholder rights risk:-
Top Institutional Holders
Position Change: ▲ Increased · ▼ Reduced · = Unchanged
Organization
Report Date
% Shares
No. Shares
Value (USD)
Change %
Top Mutual Funds
Position Change: ▲ Increased ▼ Decreased = Unchanged
Fund
Report Date
% Shares
No. Shares
Value (USD)
Change %
Recent Insider Trades
Executive / Insider
Title
Date
Action
Shares
Options Chain
CALLS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
PUTS
Strike
Last
Bid
Ask
Vol.
O.I.
IV
Sentiment Metrics
Put/Call Ratio (Volume):-
Put/Call Ratio (O.I.):-
Max Pain (estimated):-
Total O.I. Calls:-
Total O.I. Puts:-
Expected move
Average IV (Calls ATM):-
Average IV (Puts ATM):-
Days to Expiration:-
Expected move (±):-
IQVIA Holdings Inc. (IQV) SEC filings: 10-K, 10-Q and 8-K
Direct links to financial reports filed with the SEC.
IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.
A free account saves your simulator portfolios, your personal portfolio and your Academy progress, synced across devices. And, if you switch it on, the email alert the same day an insider buys stock in their own company.
No card. No spam.
IQVIA Holdings Inc. (IQV): Quantitative Analysis
IQVIA Holdings Inc. (IQV) — Healthcare — Diagnostics & Research. IQV is in the S&P 500 today. Model factor scores and market data, recalculated every trading day.
So far in 2026, IQV has returned +16.5% against +11.4% for the S&P 500 (SPY): total return, dividends included on both sides, from Dec 31, 2025 to Nov 3, 2026.
IQV ranks 366 of 461 on today's multifactor score, and 46 of the 55 Healthcare companies that score. Its strongest factor is momentum (Z 0.25, ranked 165 of 494); its weakest is quality (Z -0.70, ranked 425 of 468). Each factor ranks only the companies with data for it, and the multifactor score only those with all four: that is why the totals differ.
Factor scores
The Z-Score is how many standard deviations the company sits from the index average: 0 is average, positive is better than average, negative is worse.
IQVIA has no announced date in the Nasdaq public calendar checked (Nov 3, 2026 to Dec 7, 2026). Of its last 12 earnings announcements: 12 before the open (SEC filings through Oct 27, 2026). IQV earnings dates and times, quarter by quarter →
What is IQVIA's P/E ratio?
IQVIA's P/E (price over earnings per share for the last twelve months) is 31.9 at the Nov 3, 2026 close. That EPS is the 12-month diluted figure from the SEC, the four quarters ended Sep 30, 2026. The median of the 54 Healthcare companies with a P/E is 30.5, and the S&P 500's, 23.5: IQVIA is above its sector median. Healthcare stocks, company by company →
Where does IQVIA rank on Quant500?
In the Nov 3, 2026 multi-factor ranking, IQVIA ranks 366 of 461, and 46 of the 55 Healthcare companies that score. The ranking orders S&P 500 companies by the average of four factors (momentum, value, quality and growth) and is recalculated every trading day. It is a model output, not investment advice. The full ranking →How it is calculated →
Have IQVIA insiders bought or sold shares?
SEC Form 4 shows no open-market purchase of IQVIA shares from August 2025 through Nov 3, 2026. The latest sale was on Sep 2, 2026, by an officer, for $697k. In total, from August 2025 through Nov 3, 2026: 0 purchases and 9 sales by directors, officers and large shareholders. All IQV insider trades →
What sector is IQVIA in, and which index?
IQVIA is classified in the Healthcare sector (industry: Diagnostics & Research), per the data provider's classification (similar to GICS, not identical). It is in the S&P 500 today. It is one of the 59 S&P 500 companies in that sector. Healthcare stocks →
What is behind these numbers
The concepts on this page, explained from scratch in the Academy. Free, no account.
Quality and low volatilityWhere the quality score comes from, and why it is the factor with the most competing definitions, all of them called the same thing.
We save the portfolios you design, your own portfolio and your Academy progress, synced across devices.
Free, no card. Two automatic emails and no more: the one that confirms your address and the welcome one. After that, nothing you do not switch on yourself in your profile — such as the alert for insider buys, the same day they are reported to the SEC.